☆ 4.6 Article

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

S. Guerrieri et al.

Summary: This study found variable antibody production in multiple sclerosis patients receiving fingolimod or ocrelizumab treatments after receiving a complete SARS-CoV-2 vaccination course. Clinical features did not show a clear correlation with serological response. There is currently insufficient data to recommend against COVID-19 vaccination in these patients.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon et al.

Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Clinical Neurology

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

Anthony T. Reder et al.

Summary: The study revealed that comorbidities, obesity, and Black/African ancestry were major risk factors for SARS-CoV-2 infection in patients with multiple sclerosis (PwMS). It also found that interferons and glatiramer acetate were associated with reduced COVID-19 risk, while anti-CD20 therapies were linked to increased risk within the treated MS cohort.

CNS DRUGS (2021)

Add to Collection

Article Clinical Neurology

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

Amber Salter et al.

Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.

JAMA NEUROLOGY (2021)

Add to Collection

Review Immunology

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement

Saul Reyes et al.

Summary: This consensus statement offers updated recommendations for the management of multiple sclerosis (MS) during the COVID-19 crisis and post-pandemic period, covering a range of aspects such as telemedicine implementation, use of disease-modifying therapies, and management of MS relapses.

JOURNAL OF NEUROIMMUNOLOGY (2021)

Add to Collection

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

Add to Collection

Letter Clinical Neurology

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies

Christoph Friedli et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron et al.

Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Immunology

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ling Ni et al.

IMMUNITY (2020)

Add to Collection

Review Medicine, General & Internal

Treatment of Multiple Sclerosis: A Review

Stephen L. Hauser et al.

AMERICAN JOURNAL OF MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

Celine Louapre et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Jan C. Holter et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Medicine, General & Internal

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J. William L. Brown et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.